본문 바로가기
KERD
논문KCI 등재

The antibacterial effect of fatty acids on Helicobacter pylori infection

이상우|정성우
대한내과학회 (The Korean Association Of Internal Medicine)|2016.01|The Korean Journal of Internal Medicine|제31권 제1호|pp. 30-35|DOI http://dx.doi.org/10.3904/kjim.2016.31.1.30

2

조회

0

다운로드

1

인용

0

참고문헌

키워드

LiposomesAnti-bacterial agentsFatty acidsHelicobacter pyloriDrug delivery systems
주제분류내과학

초록

Eradication of Helicobacter pylori is recommended for the management of various gastric diseases, including peptic ulcers and mucosa-associated lymphoid tissue lymphoma. Because of the increasing prevalence of antibiotic resistance, the eradication rates of antibiotic-based therapies have decreased. Therefore, alternative treatments should be considered. The antibacterial properties of fatty acids (FAs) have been investigated in various organisms, including H. pylori. Some FAs, particularly polyunsaturated FAs, have been shown to have bactericidal activity against H. pylori in vitro; however, their antibacterial effects in vivo remain controversial. Poor solubility and delivery of FAs may be important reasons for this discrepancy. Recently, a series of studies demonstrated the antibacterial effects of a liposomal formulation of linolenic acid against H. pylori, both in vitro and in vivo. Further research is needed to improve the bioavailability of FAs and apply them in clinical use.

Abstract

Eradication of Helicobacter pylori is recommended for the management of various gastric diseases, including peptic ulcers and mucosa-associated lymphoid tissue lymphoma. Because of the increasing prevalence of antibiotic resistance, the eradication rates of antibiotic-based therapies have decreased. Therefore, alternative treatments should be considered. The antibacterial properties of fatty acids (FAs) have been investigated in various organisms, including H. pylori. Some FAs, particularly polyunsaturated FAs, have been shown to have bactericidal activity against H. pylori in vitro; however, their antibacterial effects in vivo remain controversial. Poor solubility and delivery of FAs may be important reasons for this discrepancy. Recently, a series of studies demonstrated the antibacterial effects of a liposomal formulation of linolenic acid against H. pylori, both in vitro and in vivo. Further research is needed to improve the bioavailability of FAs and apply them in clinical use.

참고문헌 (40)

  1. Suerbaum S, "Helicobacter pylori infection", N Engl J Med, 347, pp.1175~1186 (2002)
  2. Malfertheiner P, "Management of Helicobacter pylori infection: the Maastricht IV", Florence Consensus Report, 2012, pp.61, 646~664
  3. David Y. Graham, "Roadmap for elimination of gastric cancer in Korea", The Korean Journal of Internal Medicine, 30(2), pp.133~139 (2015), 대한내과학회[DOI]
  4. Vakil N, "Eradication therapy for Helicobacter pylori", Gastroenterology, 133, pp.985~1001 (2007)
  5. De Francesco V, "Worldwide H. pylori antibiotic resistance: a systematic review", J Gastrointestin Liver Dis, 19, pp.409~414 (2010)
  6. 방창석, "Time to learn from the past and prepare for the future in Helicobacter pylori eradication", The Korean Journal of Internal Medicine, 30(6), pp.789~791 (2015), 대한내과학회[DOI]
  7. Gisbert JP, "Rescue therapy for Helicobacter pylori infection 2012", Gastroenterol Res Pract, 2012, pp.974594~ (2012)
  8. Chuah SK, "A new look at anti-Helicobacter pylori therapy", World J Gastroenterol, 17, pp.3971~3975 (2011)
  9. Kabara JJ, "Fatty acids and derivatives as antimicrobial agents", Antimicrob Agents Chemother, 2, pp.23~28 (1972)
  10. Desbois AP, "Antibacterial free fatty acids: activities, mechanisms of action and biotechnological potential", Appl Microbiol Biotechnol, 85, pp.1629~1642 (2010)
  11. Hazell SL, "Influence of media supplements on growth and survival of Campylobacter pylori", Eur J Clin Microbiol Infect Dis, 8, pp.597~602 (1989)
  12. Hazell SL, "Unsaturated fatty acids and viability of Helicobacter(Campylobacter)pylori", J Clin Microbiol, 28, pp.1060~1061 (1990)
  13. Thompson L, "Inhibitory effect of polyunsaturated fatty acids on the growth of Helicobacter pylori: a possible explanation of the effect of diet on peptic ulceration", Gut, 35, pp.1557~1561 (1994)
  14. Khulusi S, "The effects of unsaturated fatty acids on Helicobacter pylori in vitro", J Med Microbiol, 42, pp.276~282 (1995)
  15. Petschow BW, "Susceptibility of Helicobacter pylori to bactericidal properties of medium-chain monoglycerides and free fatty acids", Antimicrob Agents Chemother, 40, pp.302~306 (1996)
  16. Bergsson G, "Bactericidal effects of fatty acids and monoglycerides on Helicobacter pylori", Int J Antimicrob Agents, 20, pp.258~262 (2002)
  17. Sun CQ, "Antibacterial actions of fatty acids and monoglycerides against Helicobacter pylori", FEMS Immunol Med Microbiol, 36, pp.9~17 (2003)
  18. Correia M, "Docosahexaenoic acid inhibits Helicobacter pylori growth in vitro and mice gastric mucosa colonization", PLoS One, 7, pp.e35072~ (2012)
  19. Simopoulos AP, "Omega-3 fatty acids in inflammation and autoimmune diseases", J Am Coll Nutr, 21, pp.495~505 (2002)
  20. Calder PC, "n-3 polyunsaturated fatty acids, inflammation, and inflammatory diseases", Am J Clin Nutr, 83(6Suppl), pp.1505S~1519S (2006)
  21. Kohli P, "Resolvins and protectins: mediating solutions to inflammation", Br J Pharmacol, 158, pp.960~971 (2009)
  22. Zhang MJ, "Resolvins: anti-inflammatory and proresolving mediators derived from omega-3 polyunsaturated fatty acids", Annu Rev Nutr, 32, pp.203~227 (2012)
  23. Correia M, "Crosstalk between Helicobacter pylori and gastric epithelial cells is impaired by docosahexaenoic acid", PLoS One, 8, pp.e60657~ (2013)
  24. Lee SE, "Anti-inflammatory mechanism of polyunsaturated fatty acids in Helicobacter pylori-infected gastric epithelial cells", Mediators Inflamm, 2014, pp.128919~ (2014)
  25. Miller TA, "Protective effects of prostaglandins against gastric mucosal damage: current knowledge and proposed mechanisms", Am J Physiol, 245(5 Pt 1), pp.G601~G623 (1983)
  26. Duggan AE, "Clarification of the link between polyunsaturated fatty acids and Helicobacter pylori-associated duodenal ulcer disease: a dietary intervention study", Br J Nutr, 78, pp.515~522 (1997)
  27. Frieri G, "Polyunsaturated fatty acid dietary supplementation: an adjuvant approach to treatment of Helicobacter pylori infection", Nutr Res, 20, pp.907~916 (2000)
  28. Yu HN, "Effects of fish oil with a high content of n-3 polyunsaturated fatty acids on mouse gut microbiota", Arch Med Res, 45, pp.195~202 (2014)
  29. Pagkalos VA, "Fatty acid composition of subcutaneous adipose tissue and gastric mucosa:is there a relation with gastric ulceration?", BMC Gastroenterol, 9, pp.9~ (2009)
  30. Meier R, "Fish oil (Eicosapen) is less effective than metronidazole, in combination with pantoprazole and clarithromycin, for Helicobacter pylori eradication", Aliment Pharmacol Ther, 15, pp.851~855 (2001)
  31. Khandouzi N, "Comparison of the effects of eicosapentaenoic acid and docosahexaenoic acid on the eradication of Helicobacter pylori infection, serum inflammatory factors and total antioxidant capacity", Iran J Pharm Res, 14, pp.149~157 (2015)
  32. Lacey RW, "Sensitivity of staphylococci to fatty acids: novel inactivation of linolenic acid by serum", J Med Microbiol, 14, pp.41~49 (1981)
  33. Dyall SC, "Methodological issues and inconsistencies in the field of omega-3 fatty acids research", Prostaglandins Leukot Essent Fatty Acids, 85, pp.281~285 (2011)
  34. Glassman HN, "Surface active agents and their application in bacteriology", Bacteriol Rev, 12, pp.105~148 (1948)
  35. Torchilin VP, "Recent advances with liposomes as pharmaceutical carriers", Nat Rev Drug Discov, 4, pp.145~160 (2005)
  36. Allen TM, "Liposomal drug delivery systems:from concept to clinical applications", Adv Drug Deliv Rev, 65, pp.36~48 (2013)
  37. Thamphiwatana S, "Phospholipase A2-responsive antibiotic delivery via nanoparticle-stabilized liposomes for the treatment of bacterial infection", J Mater Chem B Mater Biol Med, 2, pp.8201~8207 (2014)
  38. Obonyo M, "Antibacterial activities of liposomal linolenic acids against antibiotic-resistant Helicobacter pylori", Mol Pharmacol, 9, pp.2677~2685 (2012)
  39. Jung SW, "Mechanism of antibacterial activity of liposomal linolenic acid against Helicobacter pylori", PLoS One, 10, pp.e0116519~ (2015)
  40. Thamphiwatana S, "In vivo treatment of Helicobacter pylori infection with liposomal linolenic acid reduces colonization and ameliorates inflammation", Proc Natl Acad Sci U S A, 111, pp.17600~17605 (2014)

관련 논문AI추천

Study of probiotic and simvastatin additive effect on Helicobacter pylori eradication rateAbazar Parsi, Eskandar Hajiani, Hooman Saeidian, Maryam Biuseh, Mehdi Biuseh, Samira Mohammadi, Seyed Jalal Hashemi소화기인터벤션의학회 · International Journal of Gastrointestinal Intervention2019 · 제8권 제4호Antimicrobial Characterization of Inula britannica against Helicobacter pylori on Gastric Condition백현동, NA-KYOUNG LEE, Young Hwan Lee한국미생물·생명공학회 · Journal of Microbiology and Biotechnology2016 · 제26권 제6호Plumbagin Inhibits Expression of Virulence Factors and Growth of Helicobacter pylori문철, 박민, 김사현, 김종배, 엄용빈, 우현준, 이민호한국미생물·생명공학회 · 한국미생물·생명공학회지2016 · 제44권 제2호Efficacy of Levofloxacin-Based Third-Line Therapy for the Eradication of Helicobacter pylori in Peptic Ulcer Disease김광하, 김상균, 김선문, 김재규, 김지현, 김태호, 김현수, 김흥업, 송지현, 신운건, 심기남, 이동호, 이중엽, 임주현, 전성우, 정일권, 한재필, 홍수진, 황재진거트앤리버 소화기연관학회협의회 · Gut and Liver2017 · 제11권 제2호Optimizing Helicobacter pylori Treatment: An Updated Review of Empirical and Susceptibility Test-Based TreatmentsIshibashi Fumiaki, Mochida Kentaro, Morishita Tetsuo, Nagai Mizuki, Suzuki Sho거트앤리버 소화기연관학회협의회 · Gut and Liver2023 · 제17권 제5호Influence of Helicobacter pylori Infection and Eradication Therapy on Nutrition and Metabolic ParametersMurata Masaki, Sugimoto Mitsushige거트앤리버 소화기연관학회협의회 · Gut and Liver2025 · 제19권 제3호

이 간행물의 다른 논문 (25건)

Breakthrough in heart failure with preserved ejection fraction: are we there yet?Shir Lynn Lim, Carolyn Su Ping Lampp. 1-14Emerging strategies for the treatment of pulmonary tuberculosis: promise and limitations?고원중, Wing Wai Yewpp. 15-29Can a high-flow nasal cannula substitute for noninvasive positive pressure ventilation in post-extubation respiratory failure?김제형pp. 36-39New monoclonal antibody-based test for Helicobacter pylori urease in gastric tissueWoo Jong Kim, Hyung Rag Kim, Young Do Jung, Young Eun Joo, Jae Won Beom, Do Hyun Kim, Ho Dong Kim, Hyeuk Park, Seung Choi, Chang Kook Park, Young Jik Lee, Ju Young Park, Chul Parkpp. 40-45Feasibility of α-fetoprotein as a diagnostic tool for hepatocellular carcinoma in KoreaJoon Hyoek Lee, Dae Geon Ahn, Yong Han Paik, 배시현, 이현웅, Hyung Joon Kim, 강현, 이준성pp. 46-53
원문 보기